title: [Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
abstract: We report a case of metastatic renal cancer as a second malignancy in a patient with chronic lymphocytic leukemia (CLL). Six years after the primary CLL diagnosis, the clinical presentation of this patient was not typical for CLL, requiring further diagnostic steps. Due to the long-lasting course of CLL second cancers can occur in these patients. In addition some forms of tumors, such as Kaposi sarkoma, malignant melanoma, laryngeal carcinoma, lung cancer and Hodgkin Lymphoma are found more frequently in this patient population. Men with CLL have an increased risk for brain tumors, women for gastric and bladder cancers.
authors.affiliation: Zentrum für Onkologie/Hämatologie und Transfusionsmedizin, Kantonsspital Aarau.
authors.forename: P
authors.initials: P
authors.lastname: Sendi
authors.forename: E
authors.initials: E
authors.lastname: Puric
authors.forename: A
authors.initials: A
authors.lastname: Schönenberger
authors.forename: M
authors.initials: M
authors.lastname: Bargetzi
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001132:Arm; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D006801:Humans; D006987:Hypesthesia / Q000209:etiology; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications*; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008279:Magnetic Resonance Imaging; D008297:Male; D018908:Muscle Weakness / Q000209:etiology; D016609:Neoplasms, Second Primary; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use; D011860:Radiography, Abdominal; D013902:Radiography, Thoracic; D012306:Risk; D012307:Risk Factors; D012737:Sex Factors; D000077157:Sorafenib; D013160:Splenic Neoplasms / Q000556:secondary; D000077210:Sunitinib; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib